Business Context and Reporting Period
This Form 8-K is a current report filed by Synta Pharmaceuticals Corp. (not Madrigal Pharmaceuticals, Inc., as indicated in the metadata) on March 2, 2015. The filing discloses the approval of a new Cash-Based Employee Retention and Incentive Bonus Plan by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements.
Material Changes and Plan Details
The primary material event is the establishment of a bonus plan applicable to all employees, with specific provisions for Named Executive Officers (NEOs):
- Eligibility: All employees are eligible for retention and incentive bonuses. Executive Officers (SVP level and above) are eligible only for the incentive portion.
- Performance Goals: Incentive bonuses are tied to three corporate goals related to the product development pipeline.
- Payout Structure: Bonuses range from 100% to 300% of an employee's annual target bonus. For Vice Presidents and above, the total bonus is capped at 200% of their annual target bonus.
- Payment Timing: Payments will be made in cash no later than March 15, 2016, contingent on the certification of goal achievement.
- Termination Provisions: Employees terminated without cause prior to payment remain eligible for the retention portion and any incentive portion for goals achieved as of the termination date.
Maximum Incentive Payments for Executive Officers
The following table outlines the maximum incentive payment for NEOs, expressed as a percentage of their base salary as of December 31, 2015:
| Name | Title | Max Incentive Payment (% of Base Salary) |
|---|---|---|
| Anne Whitaker | President and CEO | 120% |
| Chen Schor | EVP, COO | 100% |
| Marc Schneebaum | SVP, CFO | 80% |
| Vojo Vukovic | SVP, CMO | 80% |
| Arthur McMahon | SVP, Human Resources | 80% |
| Wendy Rieder | SVP, General Counsel | 80% |
Guidance, Outlook, and Risks
The filing does not contain financial guidance, market outlook, or general risk factors. The primary contingency noted is that bonus payments are conditional upon the achievement of specific product development goals and the employee's continued employment (or termination without cause) until the payment date.
Investor Verification Checklist
- Verify the specific product development goals set by the Committee to assess the likelihood of bonus payout.
- Confirm the base salary figures for each executive as of December 31, 2015, to calculate the actual dollar value of the potential payouts.
- Monitor the company's progress on its product pipeline between March 2015 and March 2016.
- Note the discrepancy between the metadata company name (Madrigal) and the filing registrant (Synta Pharmaceuticals).